Description: BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.
Home Page: www.bioxceltherapeutics.com
BTAI Technical Analysis
555 Long Wharf Drive
New Haven,
CT
06511
United States
Phone:
475 238 6837
Officers
| Name | Title |
|---|---|
| Dr. Vimal D. Mehta Ph.D. | Founder, CEO, Pres, & Director |
| Dr. Frank D. Yocca Ph.D. | Sr. VP & Chief Scientific Officer |
| Mr. Javier Rodriguez | Sr. VP, Chief Legal Officer & Corp. Sec. |
| Dr. Krishnan Nandabalan Ph.D. | Chief Digital Officer ?& Director |
| Mr. Richard I. Steinhart MBA | Sr. VP & CFO |
| Ms. Mary Coleman | VP of Investment Relations |
| Dr. Iris Francesconi Ph.D. | Sr. VP of Marketing, Market Research & Commercial Assessments |
| Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P. | Sr. VP & Chief Medical Officer |
| Dr. Cedric Burg | VP and Head of Global Clinical Operations & Project Management |
| Dr. Chetan D. Lathia Ph.D. | Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9656 |
| Price-to-Sales TTM: | 4131.888 |
| IPO Date: | 2018-03-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |